Brief: Elicio Therapeutics Announces Positive Recommendation By Idmc To Continue Eli-002 7P Randomized Phase 2 Study In Pancreatic Cancer Without Modifications To Final Analysis
05/08/2025 12:57
Elicio Therapeutics Inc ELTX.O: ELICIO THERAPEUTICS ANNOUNCES POSITIVE RECOMMENDATION BY IDMC TO CONTINUE ELI-002 7P RANDOMIZED PHASE 2 STUDY IN PANCREATIC CANCER WITHOUT MODIFICATIONS TO FINAL ANALYSIS ELICIO THERAPEUTICS INC - FINAL DFS ANALYSIS EXPECTED IN Q4 2025 ELICIO THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q1 2026 ELICIO THERAPEUTICS INC - IDMC CONFIRMS SAFETY PROFILE OF ELI-002 7P Source text: ID:nGNX8mRDWT Further company coverage: ELTX.O
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)